Our results show that targeting the CCL2/CCR2 and CXCLs/CXCR2 axes in the context of TACE treatment reduces the infiltration of neutrophils and macrophages and the activation of hepatic progenitor cells, thus overcoming the TACE resistance of HCC. The gene discussed is CCR2; the disease is hepatocellular carcinoma.